Aktienanalyse zu Pulse Biosciences Inc (PLSE)PLSEPulse Biosciences Inc

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Pulse Biosciences Inc is a good buy right now due to its recent price surge and positive analyst ratings. The current price is $47.57, while analysts have set price targets as high as $45, indicating potential upside. Additionally, the company's gross margin improved significantly to 37.1% in Q2 2026, which is a strong indicator of operational efficiency. However, the main risk is the negative earnings per share (EPS) of -0.36 reported in the last earnings, which reflects ongoing financial challenges that investors should monitor closely.